Development of computerized alerts with management strategies for 25 serious drug-drug interactions

American Journal of Health-System Pharmacy

Volumn 66, Issue 1, 2009, Pages 38-44

  Murphy, John E ^a   Malone, Daniel C ^a   Olson, Bridget M ^b   Grizzle, Amy J ^c   Armstrong, Edward P ^a   Skrepnek, Grant H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b Dymaxium Inc   (United States)

^c Center for Health Outcomes and PharmacoEconomic Research   (United States)

Author keywords

Ambulatory care; Computers; Drug interactions; Quality assurance

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CLARITHROMYCIN; CODEINE; DIHYDROERGOTAMINE; ERGOT ALKALOID; ERGOTAMINE; ERYTHROMYCIN; ESTAZOLAM; FLUCONAZOLE; FROVATRIPTAN; ITRACONAZOLE; LORAZEPAM; MACROLIDE; MIDAZOLAM; OXAZEPAM; PARACETAMOL; POSACONAZOLE; PYRROLE DERIVATIVE; QUAZEPAM; RIZATRIPTAN; SEROTONIN DERIVATIVE; SUMATRIPTAN; TRIAZOLAM; TRIPTAN DERIVATIVE; TROLEANDOMYCIN; UNINDEXED DRUG; VORICONAZOLE; ZOLMITRIPTAN;

AMBULATORY CARE; ARTICLE; AUTOMATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INFORMATION; DRUG METABOLISM; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; HUMAN; PATIENT CARE; PRIORITY JOURNAL; COMPUTER ASSISTED DRUG THERAPY; DRUG INTERACTION; HOSPITAL INFORMATION SYSTEM; MEDICATION ERROR; METHODOLOGY; PRESCRIPTION; STANDARD;

AMBULATORY CARE; DRUG INFORMATION SERVICES; DRUG INTERACTIONS; DRUG THERAPY, COMPUTER-ASSISTED; ELECTRONIC PRESCRIBING; HUMANS; MEDICAL ORDER ENTRY SYSTEMS; MEDICATION ERRORS;

EID: 62449276097     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070046     Document Type: Article

References (24)

1. Glassman PA, Simon B, Belperio P et al. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care. 2002; 40:1161-1171
2. Peterson JF, Bates DW. Preventable medication errors: identifying and eliminating serious drug interactions. J Am Pharm Assoc. 2001; 41:159-160
3. Weingart SN, Toth M, Sands DZ et al. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med. 2003; 163:2625-2631 (Pubitemid 37464421)
4. Chui MA, Rupp MT. Evaluation of online prospective DUR programs in community pharmacy practice. J Manag Care Pharm. 2000; 6:27-32.
5. Chen YF, Avery AJ, Neil KE et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf. 2005; 28:67-80.
6. Murphy JE, Forrey RA, Desiraju U. Community pharmacists' responses to drug-drug interaction alerts. Am J Health-Syst Pharm. 2004; 61:1484-1487 (Pubitemid 39481422)
7. Armstrong EP, Denemark CR. How pharmacists respond to on-line, real-time DUR alerts. J Am Pharm Assoc. 1998; 38:149-154
8. Armstrong EP, Markson TJ. On-line DUR messages: pharmacists' attitudes and actions in response. J Am Pharm Assoc. 1997; NS37:315-320
9. Magnus D, Rodgers S, Avery AJ. GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther. 2002; 27:377-382 (Pubitemid 35286237)
10. Fulda TR, Baluck RJ, Vander Zanden J et al. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res. 2000; 61:540-548
11. Abarca J, Malone DC, Armstrong EP et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc. 2004; 44:136-141
12. Hazlet TK, Lee TA, Hansten PD et al. Performance of community pharmacy drug interaction software. J Am Pharm Assoc. 2001; 41:200-204
13. Abarca J, Colon LR, Wang VS et al. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm. 2006; 12:383-389 (Pubitemid 47400595)
14. Abarca J, Malone DC, Skrepnek GH et al. Community pharmacy managers' perception of computerized drug-drug interaction alerts. J Am Pharm Assoc. 2006; 46:148-153 (Pubitemid 46037371)
15. Malone DC, Abarca J, Hansten PD et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc. 2004; 44:142-151 (Pubitemid 41200508)
16. Zucchero FJ, Hogan MJ, Sommer CD et al. Evaluations of drug interactions: the standard for drug interactions. St. Louis: First DataBank, Inc.; 2001.
17. Hansten PD, Horn JR. Drug interactions: analysis and management, a clinical perspective and analysis of current developments. St. Louis: Facts and Comparisons, Inc.; 2001.
18. Tatro DS. Drug interaction facts. St. Louis: Facts and Comparisons, Inc.; 2001.
19. Micromedex Healthcare Series Drug REAX. Greenwood Village, CO: Micromedex; 2002.
20. Dipiro JT, Talbert RL, Yee GC et al. Pharmacotherapy: a pathological approach. 5th ed. San Francisco: McGraw-Hill Medical; 2002.
21. Koda-Kimble MA, Young LY. Applied therapeutics: the clinical use of drugs. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
22. AHFS drug information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007.
23. Bergk V, Gasse C, Rothenbacher D et al. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther. 2004; 76:85-96.
24. Bergk V, Gasse C, Schnell R et al. Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol 2004; 60:595-602. (Pubitemid 39517914)